ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma

Melanomas are characterized by activating “driver” mutations in BRAF, NRAS, KIT, GNAQ, and GNA11. Resultant mitogen-activated protein kinase (MAPK) pathway signaling makes some melanomas susceptible to BRAF (BRAF V600 mutations), MEK1/2 (BRAF V600, L597, fusions; NRAS mutations), or other kinase inh...

Descripción completa

Detalles Bibliográficos
Autores principales: Hutchinson, Katherine E., Johnson, Douglas B., Johnson, Adam S., Sanchez, Violeta, Kuba, Maria, Lu, Pengcheng, Chen, Xi, Kelley, Mark C., Wang, Qingguo, Zhao, Zhongming, Kris, Mark, Berger, Michael F., Sosman, Jeffrey A., Pao, William
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4673168/
https://www.ncbi.nlm.nih.gov/pubmed/26084293

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4673168/
https://www.ncbi.nlm.nih.gov/pubmed/26084293

Ejemplares similares